Exelixis Analyst Report: Riding the Evolutions Issued by BrokerBank Securities, Inc.
NEW YORK, Jan. 5, 2015 /PRNewswire/ -- Exelixis, Inc. (NASDAQ: EXEL) is a biotechnology company that develops and markets treatments for cancer. The company is in its development stage with one approved treatment. The two most advanced assets of the company are cabozantinib (Cabo), and cobimetinib (Cobi). EXEL has five Phase III trials for various cancer treatments using Cabo and Cobi. On top of those, the company has numerous strategic partnerships with other drug companies, and multiple treatments in Phase II trials. EXEL has a huge pipeline of potential uses for its treatments.
By filing its New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA) for Cobi, on December 15, 2014, EXEL could benefit from the $3.4 billion melanoma market in the United States, which continues to grow until 2020. EXEL also targeted late-stage studies on Cabo in metastatic renal cell carcinoma (RCC), a $1 billion market with fewer players, plenty of room for enhancements, and lots of market shares.
An analyst brief which covers a brief technical analysis, recommendation and price target can be viewed in its entirety by using the link below. There is no cost obligation required to view this report:
http://bit.ly/-EXEL--AnalystReport
Copy and paste to browser may be required.
Forward-Looking Disclaimer
This report may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward- looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of mentioned company to be materially different from the statements made herein.
Not Financial Advice
BrokerBank Securities, Inc. make no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
Compliance Procedure
Content is researched, written and reviewed on a best-effort basis by a 3rd party research analyst. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below. We do not engage in high frequency trading.
A full disclaimer can be found by viewing the analyst report.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
BrokerBank Securities, Inc. is a member of the Financial Industry Regulatory Authority, CRD number #130116.
SOURCE BrokerBank Securities, Inc.
Related Links
http://www.brokerbanksecurities.com
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article